Bisphenol A interacts with the estrogen receptor α in a distinct manner from estradiol

Molecular and Cellular Endocrinology

Volumn 142, Issue 1-2, 1998, Pages 203-214

  Gould, Janet C ^a   Leonard, Linda S ^a   Maness, Susan C ^a   Wagner, Brandee L ^b   Conner, Kevin ^c   Zacharewski, Tim ^d   Safe, Steve ^c   McDonnell, Donald P ^b   Gaido, Kevin W ^a  

^a CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Anti estrogen; Bisphenol A; Estrogen; HepG2 cells; Receptor; Uterotrophic assay

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ESTRADIOL; ESTRIOL; ESTROGEN RECEPTOR; ESTRONE; FULVESTRANT; HYDROXYTAMOXIFEN; PARTIAL AGONIST; PEROXIDASE; PROGESTERONE RECEPTOR; RALOXIFENE; RECEPTOR SUBTYPE;

ARTICLE; CELL CULTURE; CLASSIFICATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UTERUS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS, NON-STEROIDAL; FEMALE; HUMANS; LIVER NEOPLASMS; MUTAGENESIS; ORGAN SIZE; PEROXIDASE; PHENOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSFECTION; TUMOR CELLS, CULTURED; UTERUS;

EID: 0032566153     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(98)00084-7     Document Type: Article

References (45)

1. Arnold S.F., Robinson M.K., Notides A.C., Guillette L.J. Jr., McLachlan J.A. A yeast estrogen screen for examining the relative exposure of cells to natural and xenoestrogens. Environ. Health Perspect. 104(5):1996;544-548.
2. Berry M., Metzger D., Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type an dpromoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9(9):1990;2811-2818.
3. Black L.J., Sato M., Rowley E.R., Magee D.E., Bekele A., Williams D.C., Cullianan G.J., Bendele R., Kauffman R.F., Bensch W.R., Frolik C.A., Termine J.D., Bryant H.U. Raloxifene (LY1394881 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93:1994;63-69.
4. Bond, G.P., McGinnis, P.M., Cheever, K.L., Harris, S.J., Plotnick, H.B., Niemeler, R.W., 1980. Reproductive effects of Bisphenol A. Society of Toxicology Abstracts.
5. Brotons J.A., Olea-Serrano M.F., Villalobos M., Pedraza V., Olea N. Xenoestrogens released from lacquer coatings in food cans. Environ. Health Perspect. 103:1995;608-612.
6. Bunone G., Briand P.-A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15(9):1996;2174-2183.
7. Chalbos D., Philips A., Galtier F., Rochefort H. Synthetic anti-estrogens modulate induction of pS2 and cathepsin D messenger ribonucleic acid by growth factors and adenosine 3′,5′-monophosphate in MCF7 cells. Endocrinology. 133:1993;571-576.
8. Colborn T., vom Saal F. S., Soto A. M. Developmental effects of endocrine disrupting chemicals in wildlife and humans. Environ. Health Perspect. 101(5):1993;378-384.
9. Davis D.L., Bredlow H.L., Wolff M., Woodruff T., Hoel D.G., Anton-Culver H. Medical hypothesis: Xenoestrogens as preventable causes of breast cancer. Environ. Health Perspect. 101:1993;372-377.
10. Evans G., Bryant H.U., Sato M., Turner R.T. Taloxifene is a tissue specific estrogen agonist. J. Bone. Miner. Res. 8(Suppl 2):1993;134.
11. Gaido K.W., Leonard L., Lovell S., Gould J., Babai D., Portier C., McDonnell D. Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. Toxicol. Appl. Pharmacol. 143:1997;205-212.
12. Gorman C.M., Moffat L.F., Howard B.H. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1982;1044-1051.
13. Ignar-Trowbridge D.M., Pimentel M., Parker M.G., McLachlan J.A., Korach K.S. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology. 137(5):1996;1735-1744.
14. Ignar-Trowbridge K.M., Nelson K.G., Bidwell M.C., Curtis S.W., Washburn T.F., Mclachlan J.A., Korach K.S. Coupling of dual signaling pathways: Epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. USA. 89:1992;4658-4662.
15. Ignar-Trowbridge K.M., Teng C.T., Ross K.A., Parker M.G., Korach K.S., McLachlan J.A. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol. Endocrinol. 7:1993;992-998.
16. Jordan V.C., Fritz N.F., Tormey D.C. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration of node-positive patients with breast cancer. Cancer Res. 47:1987;624-630.
17. Kalkhoven E., Wissink S., van der Saag P.T., van der Burg B. Negative interaction between the RelA(p65) subunit of NF-κB and the progestrone receptor. J. Biol. Chem. 271(11):1996;6217-6224.
18. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H., Metzger D., Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494.
19. Katzenellenbogen J.A., O'Malley B.W., Katzenellenbogen B.S. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell and promoter-specific action of these hormones. Mol. Endocrinol. 10(2):1996;119-131.
20. Koike S., Sakai M., Muramatsu M. Molecular cloning and characterization of rat estrogen receptor cDNA. Nucleic Acids Res. 15(6):1987;2499-2513.
21. Krishnan A.N., Stathis P., Permuth S.F., Tokes L., Feldman D. Bisphenol-A: An estrogenic substance is released from polycarbonate flasks during autoclaving. Endocrinology. 132(6):1993;2279-2286.
22. Kuiper G.G.J.M., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and b. Endocrinology. 138:1997;863-870.
23. Kumar V., Green S., Stack G., Berry M., Jin J.R., Chambon P. Functional domains of the human estrogen receptor. Cell. 51(6):1987;941-951.
24. Love R.R., Mazess R.B., Barden H.S., Epstein S., Newcomb P.A., Jordan V.C., Carbone P.P., DeMets D.L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New Engl. J. Med. 326:1992;852-856.
25. McDonnell D.P., Clemm D.L., Hermann T., Goldman M.E., Pike J.W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 9(6):1995;659-669.
26. McInerney E.M., Tsai N.J., O'Malley B.W., Katzenellenbogen B.S. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc. Natl. Acad. Sci. USA. 93:1996;10069-10073.
27. Morrissey R.E., George J.D., Price C.J., Tyl R.W., Marr M.C., Kimmel C.A. The developmental toxicity of bisphenol A in rats and mice. Fundam. Appl. Toxicol. 8:1987;571-582.
28. National Research Council, 1996. Guide for the Care and Use of Laboratory Animals, National Academic Press, Washington, DC, pp. 125.
29. Obourn J.D., Koszewski N.J., Notides A.C. Hormone- and DNA-binding mechanisms of the recombinant human estrogen receptor. Biochemistry. 32:1993;6229-6239.
30. Olea N., Pulgar R., Perez P., Olea-Serrano F., Rivas A., Novillo-Fertrell A., Pedraza V., Soto A.M., Sonnenschein C. Estrogenicity of resin-based composites and sealants used in dentistry. Environ. Health Perspect. 104(3):1996;298-305.
31. Papaconstantinou A.D., Brown K.M., Lappas N.T., Fisher B.R., Umbreit T.H. Estrogenicity and heat shock proteins: Bisphenol A. Toxicologist. 42(1):1998;175.
32. Potthoff S.J., Romine L.E., Nardulli A. Effects of wild type and mutant estrogen receptors on DNA flexibility, DNA bending, and transcription activation. Mol. Endocrinol. 10(9):1996;1095-1106.
33. Reel, J.R., George, J.D., Lawton, A.D., Myers, C.B., Lamb, J.C., 1985, Bisphenol A: Reproduction and fertility assessment in CD-1 mice when administered in feed. NTP/NIEHS Report.
34. Renaud J.P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., Moras D. Crystal structure of the RAT-γ ligand-binding domain bound to all bans retinoic acid. Nature. 378:1995;681-689.
35. Robertson D.W., Katzenellenbogen J.A., Long D.J., Rorke E.A., Katzenellenbogen B.S. Tamoxifen anti-estrogens. A comparison of the activity, pharmacokinetics and metabolic activation of the cis and trans isomers of tamoxifen. J. Steroid Biochem. 16:1982;1-13.
36. Sharpe R.M., Fisher J.S., Millar M.M., Jobling S., Sumpter J.P. Gestational and lactational exposure of rats to xenoestrogens results in reduced testicular size and sperm production. Environ. Health Perspect. 103(12):1995;1136-1143.
37. Smith C.L., Conneely O.M., O'Malley B.W. Modulation of ligand-independent activation of the human estrogen receptor by hormone and anti-hormone. Proc. Natl. Acad. Sci USA. 90:1993;6120-6124.
38. Soto A.M., Sonnenschein C., Chung K.L., Fernandez M.F., Olea N., Serrano F.O. The E-SCREEN assay as a tool to identify estrogens: An update on estrogenic environmental pollutants. Environ. Health Perspect. 103(Suppl. 7):1995;113-122.
39. Steinmetz R., Brown N.G., Allen D.L., Bigsby R.M., Ben-Jonathan N. The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo. Endocrinology. 138(5):1997;1780-1786.
40. Tasset D., Tora L., Fromental C., Scheer E., Chambon P. Distinct classes of transcriptional activating domains function by different mechanisms. Cell. 62:1990;1177-1187.
41. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E., Chambon P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell. 59(3):1989;477-487.
42. Tzukerman M.T., Esty A., Santiso-Mere D., Danielian P., Parker M.G., Stein R.B., Pike J.W., McDonnell D.P. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrionol. 8:1994;21-30.
43. Villalobos M., Olea N., Brotons J.A., Olea-Serrano F., Ruiz de Almodovar J.M., Pedraza V. The E-screen assay: A comparison of different MCF7 cell stocks. Environ. Health Perspect. 103(9):1995;844-850.
44. Wakeling A.E., Dukes M., Bowler J. A potent specific pure anti-estrogen with clinical potential. Cancer Res. 51:1991;3867-3873.
45. Willson T.M., Norris J.D., Wagner B.L., Asplin I., Baer P., Brown H.R., Jonew S.A., Henke B., Sauls H., Worfe S., Morris D.C., McDonnell D.P. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology. 138(9):1997;3901-3911.